Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 2/20 | 0.55 |
| ▸ | CCNK | O75909 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 3/20 | 0.53 |
| ▸ | CCND1 | P24385 | 3/20 | 0.53 |
| ▸ | CCND2 | P30279 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 4/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074091 | 0.90 | CCND3 (0.55) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL6074312 | 0.87 | CCND3 (0.42) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL6074060 | 0.86 | CDK2 (0.54) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL6074010 | 0.85 | CDK2 (0.59) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL6073774 | 0.85 | JAK3 (0.43) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL6073785 | 0.85 | JAK3 (0.43) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL6073878 | 0.81 | CCND3 (0.53) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL6074138 | 0.81 | CDK2 (0.58) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL6073819 | 0.81 | SYK (0.62) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL6073505 | 0.81 | CCND3 (0.64) | CCND3CCNKCCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| CN-1395578-A | Byrido [2,3-d] pyrimidine-2, 7-diamine kinase inhibitors | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | CCND3 98/4885CCNK 7/4885CCNA2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.